Das Pharmaunternehmen Eli Lilly and Company (LLY) hat am Sonntag, den 30. März 2025, einen Bericht über seine Ergebnisse der…
…
After starting 2024 strong, Eli Lilly (NYSE: LLY) did not perform well in the second half of last year. Its…
(Wirkstoffname berichtigt: 1. Absatz, 2. Satz: Donanemab (statt Donemab).)
AMSTERDAM (dpa-AFX) - Die…
AMSTERDAM (dpa-AFX) - Die EU-Arzneimittelbehörde EMA hat kein grünes Licht für die Zulassung eines Alzheimer-Medikaments von…
Novo Nordisks (NYSE: NVO) is famous and celebrated for its cutting-edge obesity medication. But on Thursday, its stock felt like…
This might surprise some, but Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) has significantly lagged the market in the past…
Mounjaro and Zepbound are Eli Lillys largest sources of growth, but there is much more to the company.…
Mounjaro and Zepbound are Eli Lillys largest sources of growth, but there is much more to the company.…
Eli Lilly (LLY) closed at $852.35 in the latest trading session, marking a -1.45% move from the prior day.…
SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical…
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
The trial results are critical, as it brings Eli Lillys pill one step closer to becoming a new, needle-free alternative…
Theres a price war brewing in GLP-1 weight loss drugs, and now its going global.…
Theres a price war brewing in GLP-1 weight loss drugs, and now its going global.…
It all comes down to this...the final round of the Motley Fool Rule Breaker Investing March Market Cap Showdown! Defending…
Eli Lilly and Co (NYSE:LLY) is tightening its grip on the obesity drug market, with its injectable treatment Zepbound gaining…
Its hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug…
Copycat versions of Eli Lillys diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. Theyre…
Johnson & Johnson says it will s | Johnson & Johnson will invest $55 billion in the U.S. over the…
Eli Lilly’s diabetes and weight-loss drug Mounjaro debuts in India…
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market…
Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20…
Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from countrys drug regulator, it…
Eli Lilly (LLY) concluded the recent trading session at $822.51, signifying a -0.27% move from its prior days close.…
The S&P 500 (SNPINDEX: ^GSPC) is cooling off after rip-roaring gains of over 20% in both 2023 and 2024.
The Nasdaq…
Are you reluctant to invest in stocks right now? Thats understandable. Fear, uncertainty, and doubt have become the norm in…
Plus, Eli Lillys CEO got a pay raise, and Viking Therapeutics gets closer to bringing its Ozempic competitor to market…
In the most recent trading session, Eli Lilly (LLY) closed at $822.27, indicating a -0.22% shift from the previous trading…
Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it would…
Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and its an element you…
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth…
Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Mondays…
In this podcast, Motley Fool analyst Jason Moser and host Ricky Mulvey discuss:
The impacts of tariffs on investors and companies.
If…
In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They…
Its not too often that pharmaceutical drugs become household names, but thats happening with medicines in the weight loss market.…
Its often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We…
Eli Lilly (LLY) closed the most recent trading day at $912.76, moving -1.82% from the previous trading session.…
Telehealth firms Teladoc and LifeMD said they signed an agreement with Eli Lillys pharmacy partner to offer patients the weight-loss drug, Zepbound.…
** Shares of telehealth firm Hims & Hers NYSE:HIMS fall 9% to $37.2 premarket ** A U.S. federal judge has…
Hims & Hers (HIMS) stock falls 8% as court denies injunction on FDA ruling for Eli Lillys (LLY) Zepbound shortage.…
Whats a monster stock? In my book, its a company thats built a long track record of earnings growth thanks…
Shares of Eli Lilly rose Wednesday despite its rivals announcement.…
MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and Eli…
The great buildout for AI and GLP-1 drugs continues.…
The CHMP gives a positive opinion to Eli Lillys Jaypirca in patients with relapsed or refractory CLL in a post-BTK…
Its hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years.…
Plus, Modernas bird flu contract with the U.S. is being evaluated…
Eli Lilly announced plans to invest $27 billion in four new manufacturing sites in the United States. The pharma giant…
Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest…